RVTY
FY2026 Q1 · Calendar Q2 2026
Revvity, Inc.
Revvity's Q1 FY2026 results exceeded consensus, with adjusted EPS of $1.06 versus a $1.02 estimate and revenue of $711.1 million versus $704.1 million, on 3% organic growth and 23.6% adjusted operating margins. The defining strategic move of the quarter is the planned divestiture of the China immunodiagnostics business -- retaining a minority stake with a 2027 closing target -- which management expects to lift pro-forma growth by ~100 bps and margins by ~30 bps. AI-driven software platforms (Xynthetica, BioDesign, LabGistics) are gaining traction with 40% YoY SaaS ARR growth, though a 20% Q2 sequential decline in software revenue is expected. The market responded favorably with a 6.7% move on the report and 9.5% subsequent drift. Management raised full-year guidance.
EPS surprise+3.9%
Market move+6.7%
